Mundipharma

Mundipharma is a global network of independent associated pharmaceutical companies founded in 1952 by doctors, and brothers, Mortimer and Raymond Sackler. The company is headquartered in Cambridge, United Kingdom. Mundipharma is primarily known for its work in pain management, but it also has a growing portfolio in therapeutic areas such as oncology, respiratory, and biosimilars. The network of companies operates in over 120 countries worldwide.

History

The origins of Mundipharma trace back to the founding of Purdue Pharma by the Sackler family in the United States. The expansion of their pharmaceutical interests led to the establishment of Mundipharma as the international arm of their operations, aiming to distribute and market Purdue’s products outside of the United States.

Operations

Mundipharma's global network comprises independent associated companies that are responsible for the distribution and marketing of pharmaceutical products in their respective territories. The company's structure allows for a flexible approach to different markets, adapting to local needs and regulations. Mundipharma's portfolio includes a wide range of products, with a significant focus on pain management medications, including opioids, which have been the subject of controversy and legal challenges related to the opioid crisis.

Therapeutic Areas

Mundipharma has diversified its portfolio beyond pain management to include other therapeutic areas:

• Oncology: Developing treatments for various types of cancer.
• Respiratory: Offering products for the management of asthma and chronic obstructive pulmonary disease (COPD).
• Biosimilars: Focusing on the development and distribution of biosimilar medicines, which are biologic medical products highly similar to already approved biological medicines.

Controversies

Mundipharma has faced criticism and legal challenges related to the marketing of opioid painkillers. Similar to its associated company Purdue Pharma in the United States, Mundipharma has been accused of contributing to the global opioid crisis through aggressive marketing practices that downplayed the risks of addiction and overstatement of the benefits of opioids for chronic pain management.

Corporate Social Responsibility

Mundipharma states that it is committed to improving access to healthcare and medicines across the globe, particularly in underserved regions. The company has initiated several programs aimed at supporting healthcare professionals and patients in managing diseases and conditions effectively.

See Also

• Pharmaceutical industry
• Opioid epidemic
• Purdue Pharma
• Biosimilar

Mundipharma Resources
Latest articles Most recent articles Ongoing trials	Wikipedia